Article Sidebar

Submitted
2 October 2019
Accepted
2 October 2019
Published
3 October 2019
Download
PDF
Statistic
Read Counter : 1277 Download : 915

Main Article Content

Abstract

Hyaluronic acid (HA) is a glycosaminoglycan with a straight-chain polymer arrangement defined as the extracellular matrix constituent. High molecular weight HA has normal physicochemical, biological, and physiological properties whereas low molecular weight has the property of angiogenesis, inflammation, and suppresses apoptosis. This study occupied the samples of 35 paraffin block from poorly and well differentiated retinoblastoma tissue and 8 normal retinal block which have been collected for 4 years from 2010-2013 at Dr. Soetomo Hospital, Surabaya, Indonesia. Afterwards, the paraffin blocks were immunohistochemically examined for HA staining, expression of cell proliferation (Ki-67), and cell apoptosis to determine intratumoral aggressiveness of retinoblastoma. HA on poorly differentiated retinoblastoma stain with a high immunostaining of 76.2%, while well differentiated retinoblastoma on the highest HA staining was revealed to be at moderate level of 64.3%, and not appear in normal retina. In poorly differentiated retinoblastoma, the location of most HA stain is in the cell cytoplasm (87.5%). In the well differentiated retinoblastoma, the HA immunostaning mainly occurred in the cell membrane (73.7%). Histopathological retinoblastoma grading showed a significant correlation (p <0.01) towards several variables of HA immunostaining, Ki-67, and cell apoptosis. In addition, the histopathological retinoblastoma grading also revealed a significant correlation (p <0.01) towards the location of HA staining (cell membrane and cytoplasm). Both stainings are also play role in retinoblastoma differentiation. The malignancy of retinoblastoma can be proven by the increased HA staining at cytoplasm in poorly differentiated and associated with increased of cell proliferation along with decreased apoptosis.

Keywords

Hyaluronic acid retinoblastoma aggressiveness

Article Details

How to Cite
Soebagjo, H. D., Nurwasis, N., Bintoro, U. Y., & Soemitro, S. B. (2019). Evaluation of KI-67, Apoptosis, and Hyaluronic Acid in Grading Retinoblastoma. Folia Medica Indonesiana, 55(3), 206–212. https://doi.org/10.20473/fmi.v55i3.15504
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Berge EO, Knappskog S, Geisler S, Staalesen V, Pacal M., Puntervol P, et al (2010). Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers. Mole. Cancer 9,173
  2. Bharadwaj AG, Kovar JL, Loughman E, Elowsky C, Oakley GG, Simpson MA (2009). Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing. Am J Pathol. 174,1027-36
  3. Blundell CD, Deangelis PL, Almond A (2006). Hyaluronan: the absence of amide-carboxylate hydrogen bonds and the chain conformation in aqueous solution are incompatible with stable secondary and tertiary structure models. Biochem J 396, 487-98
  4. Clark RA, Alon R, Springer TA (1996). CD44 and hyaluronan-dependent rolling interactions of lympho-cytes on tonsillar stroma. J Cell Biol. 134, 1075-87
  5. Evanko SP, Tammi MI, Tammi RH, Wight TN (2007). Hyaluronan-dependent pericellular matrix. Advanced Drug Delivery Reviews 59, 1352-1365
  6. Gadhoum Z, Delaunay J, Maquarre E, Durand L, Lancereaux V, Qi J, et al (2004). The Effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells. Leukemia & Lymphoma 45, 1501-1510
  7. Gao H, Yao Q, Lan X, Li S, Wu J, Zeng G, Xue Y (2016). Elevated HABP1 protein expression correlates with progression and poor survival in patients with gastric cancer. OncoTargets and Therapy 9, 6711-6718
  8. Ghatak S, Hascall VC, Karamanos NK, Markwald RR, Misra S (2012). Targeting the tumor microenvi-ronment in cancer progression. In Karamanos N, editor. Extracellular Matrix: Pathobiology and Signaling. Berlin, DeGruyter, p 729-46
  9. Jaime MC, Carol ST, and Garantziotis S (2015). Size matters: Molecular weight specificity of hyaluronan effects in cell biology. International Journal of Cell Biology
  10. Leach JB, Schmidt CE (2004). Hyaluronan. In: Bowlin GL, Wnek G. Encyclopedia of biomaterials and biomedical engineering. Informa Healthcare
  11. Lee JY, and Spicer AP (2000). Hyaluronan: a multifunctional, megadalton, stealth molecule. Current Opinion in Cell Biology 12, 581-586
  12. Li JH, Wang YC, Qin CD, et al (2016). Over expression of hyaluronan promotes progression of HCC via CD44-mediated pyruvate kinase M2 nuclear translocation. Am J Cancer Res 6, 509-21
  13. Liu S, Edgerton SM, Moore DH, Thor AD (2001). Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res 7, 1716-1723
  14. Lokeshwar VB and Selzer MG (2000). Differences in hyaluronic acid-mediated functions and signaling in arterial, microvessel, and vein-derived human endothelial cells. J Biol Chem 275, 27641-27649
  15. Louderbough JMV and Schroeder JA (2011). Understanding the Dual Nature of CD44 in Breast cancer Progression. Mol Cancer Res 9,12
  16. Marques ACF (2011). Investigation of The Effect of Structured Hyaluronic Acid Surfaces On Cell Proliferation and Expression of HA Cellular Receptors: CD44 and RHAMM. A thesis. Cranfield University.
  17. McKee T and McKee JR (2008). Biochemistry in Perspective: Carcinogenesis. In: Biochemistry: The Molecular Basis of Life. 4th Ed. USA, Oxford University Press
  18. Misra S, Hascall VC, Markwald RR, Ghatak S. 2015. Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer. Front Immunol 6, 201
  19. Murai T, Miyazaki Y, Nishinakamura H, Sugahara KN, Miyauchi T, Sako Y, et al (2004). Engagement of CD44 promotes Rac activation and CD44 cleavage during tumor cell migration. J Biol Chem 279, 4541-4550
  20. Naor D (2016). Editorial: Interaction Between Hyaluronic Acid and Its Receptors (CD44, RHAMM) Regulates the Activity of Inflammation and Cancer. Front Immunol 7, 39
  21. Noble PW (2002). Hyaluronan and its catabolic products in tissue injury and repair. Matrix Biology 21, 25-29
  22. Patel S, Shaikh F, Devaraji V, Radadiya A, Shah K, Shah A, Rawal R (2017). Insights into the structural perturbations of spliced variants of CD44: a modeling and simulation approach. Journal of Biomolecular Structure and Dynamics 35, 354-367
  23. Posey JT, Soloway MS, Ekici S, Sofer M, Civantos F, Duncan RC, and Lokeshwar VB (2003). Evaluation of the Prognostic Potential of Hyaluronic Acid and Hyaluronidase (HYAL1) for prostate cancer. Cancer Research 63, 2638-2644
  24. Rangel MP, de Sá VK, Martins V, et al (2015). Tissue hyaluronan expression, as reflected in the sputum of lung cancer patients, is an indicator of malignancy. Braz J Med Biol Res. 48, 557-67
  25. Rössler A, Hinghofer-Szalkay H (2003). Hyaluronan fragments: an information-carrying system?. hypothesis. Hormone and Metabolic Research 35, 67-8
  26. Scott JE (1989). Secondary structures in hyaluronan solutions: chemical and biological implications. The Biology of Hyaluronan. Ciba Foundation Symposium 143, 6-14
  27. Siiskonen H (2013). Hyaluronan and hyaluronan synthases. A dissertation in Health Sciences. Kuopio, University of Eastern Finland
  28. Sitorus RS, Saukani G, Valk PVD (2009). The apoptosis paradox in retinoblastoma. Natural compounds and their role in apoptotic cell signaling pathways. Ann NY Acad Sci 1171, 77-86
  29. Soebagjo HD, Prastyani R, Sujuti H, Lyrawati D, Sumitro SB (2013). Profile of Retinoblastoma in East Java, Indonesia. World Journal of Medicine and Medical Science Research 1, 051-056
  30. Stern, R., A.A. Asari, and K.N. Sugahara. 2006. Hyaluronan fragments: An information-rich system. European J. Cell. Biol. 85, 699-715
  31. Tahmatzopoulos A, Papakonstantinou E, Kotakidou R, Hatzihristou D, Karakiulakis G (2012). Immunohistochemical expression of hyaluronic acid in the normal prostate, benign prostate hyperplasia and prostate carcinoma. Aristotle University Medical Journal 39, 1-6
  32. Toole BP (2002). Hyaluronan promotes the malignant phenotype. J Gly 12, 37R-42R
  33. Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, et al (2003). Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker? Cancer. 97, 1321-31
  34. Urbanska K, Sokolowska J, Szmidt M, Sysa P (2014). Proliferative and Apoptotic Activity of Glioblastoma Multiforme Cells Cultured on In Ovo Model. In Vivo 28, 541-548
  35. Voutilainen K, Anttila M, Sillanpää S, Tammi R, Tammi M, Saarikoski S, Kosma V (2003). Versican in epithelial ovarian cancer: relation to hyaluronan, clinicopathologic factors and prognosis 22, 103-15
  36. Wang W, Wu J, Zhang P, Fei X, Zong Y, Chen X, et al (2016). Prognostic and predictive value of Ki-67 in triple-negative breast cancer. Oncotarget 7, 31079-31087
  37. Wiranowska, M and Rojiani MV (2011). Extracellular Matrix Microenvironment in Glioma Progression, 12. Glioma - Exploring Its Biology and Practical Rele-vance, Dr. Anirban Ghosh (Ed.) InTech, p 257-284